Sign up Australia
Proactive Investors - Run By Investors For Investors

Cellmid convening global meeting of midkine researchers in Germany

Presentations on midkine therapies for cancer, kidney disease and heart failure.
heart highlighted on the human body
Key opinion leaders from twelve countries presenting on midkine research

Cellmid Limited (ASX:CDY) will be convening the 5th Midkine Symposium in Munich, Germany between 3rd and 5th May 2018.

The symposium will be a global meeting of key opinion leaders, clinicians and research scientists involved in midkine (MK) research.

READ: Cellmid strengthens its position in hair and skin care market with leading anti-ageing product

The event follows on the success of the previous four scientific meetings on midkine held in Sydney (2010), Istanbul (2012), Kyoto (2014) and Budapest (2016).

Assessing midkine antibodies in chronic heart failure

Midkine is a promising molecule in drug development. It is a heparin-binding growth factor that promotes cell growth, survival, differentiation and cell migration.

It is almost undetectable in healthy adults, however, is upregulated as part of the pathogenesis (development) of certain chronic diseases.

Munich has been chosen for the symposium as it is the home Ludwig Maximilian University (LMU), where researchers are currently assessing Cellmid’s midkine antibodies in a model of chronic heart failure.

READ: Cellmid enters exclusive distribution agreement for anti-ageing skincare product

The research at LMU is the subject of a recently filed patent application by Cellmid and is expected to deliver vital data and add to the company’s already substantial midkine asset portfolio.

Promoting interactions between midkine researchers

The symposium will host delegates from twelve countries with expertise in various therapeutic and diagnostic fields and will enhance interactions between leading researchers within the midkine community.

Previous meetings resulted in a number of collaborations that continue to provide vital progress for Cellmid’s therapeutic programs including the recently completed clinical studies carried out at the University of Gothenburg, Sweden.

The study in Sweden demonstrated that midkine is associated with prostate cancer progression and treatment resistance.

Symposium to be led by Dr Ludwig Weckbach

The symposium will be hosted by the team led by clinician scientist Dr Ludwig Weckbach, Cellmid’s research partner based at the Biomedical Center and Department of Cardiology, LMU.

Dr Weckbach will be welcoming symposium delegates as well presenting his group’s innovative discoveries demonstrating the clinical potential of therapeutic antibodies targeting midkine for chronic heart failure.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

July 26 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use